Clinical trials
Colorectal Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting colorectal cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,511 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07683845Recruiting
Using a tumor model to predict chemo response in pancreatic cancer
This trial tests a personalized approach by growing a miniature model of your tumor from a tissue sample. The goal is to see if this model can predict which chemotherapy will work best for you before you start treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06663007RecruitingPhase 1/Phase 2
RC48 alone or with envafolimab for advanced prostate cancer with CDK12 changes
This trial tests a drug called RC48, alone or with envafolimab, for men with a specific type of advanced prostate cancer that has not responded to standard treatments. It aims to see if this combination can shrink tumors or slow disease progression.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT07673887RecruitingPhase 3
Study of a new drug combo for advanced stomach cancer
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
Saint Louis Park, MinnesotaAges 18 years+ - NCT07680257RecruitingEarly Phase 1
CLDN18.2 CAR T cells for advanced solid tumors
This trial tests a new treatment called CLDN18.2 CAR T cells in people with advanced solid tumors that have a specific marker (CLDN18.2). It aims to see if it is safe and works against cancers that have not responded to standard treatments.
Hefei, AnhuiAges 18–75 - NCT07680205RecruitingPhase 2
Study of Belzutifan for Pheochromocytoma or Paraganglioma
This trial tests a drug called belzutifan to see how it affects hormone levels in people with rare adrenal tumors (pheochromocytoma or paraganglioma). It may help control symptoms caused by excess hormones.
Cambridge, CambridgeshireAges Any age - NCT07664150RecruitingPhase 1/Phase 2
Testing a new drug for HER2-positive cancers after other treatments stop working
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07668154RecruitingPhase 2
Testing SKB571 for advanced head and neck cancer
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
ChengduAges 18–75 - NCT07670013RecruitingPhase 2
SKB264 and glecirasib for advanced KRAS G12C lung cancer
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Hangzhou, ZhejiangAges 18–75 - NCT07664891Recruiting
Metabolism and surroundings in pancreatic cancer
This study looks at how the metabolism of pancreatic cancer cells affects their surroundings. It uses a biopsy (removing a small sample of tissue from a tumor in the pancreas, liver, or lung) to learn more about the cancer and guide treatment.
MarseilleAges 18 years+ - NCT05141474RecruitingEarly Phase 1
Personalized immune cell treatment for advanced cancers after failed therapy
This trial tests a personalized therapy made from your own immune cells (TIL) picked to match your tumor’s “neoantigens,” plus standard immune-boosting medicine (including IL-2). It’s for people with advanced epithelial or immune “resistant” solid tumors whose cancer has continued growing despite available treatments.
BarcelonaAges 18 years+ - NCT07660094RecruitingPhase 3
New treatment for advanced lung cancer that has stopped responding to immunotherapy
This trial tests a new investigational medicine (aglatimagene besadenovec) plus pembrolizumab against standard chemotherapy (docetaxel) for people with stage IV non-squamous lung cancer that has stopped responding to pembrolizumab. The new treatment is given as a tumor injection (like a biopsy) along with a pill (prodrug) and an infusion of pembrolizumab. The goal is to see if it can re-engage the immune system to fight the cancer.
New York, New YorkAges 18 years+ - NCT07659379Enrolling by invitationPhase 3
Long term extension study for gotistobart treated patients
This study is for people who have already been taking the drug gotistobart in a previous trial. It allows them to keep receiving the drug for a longer time, so doctors can see how the treatment works over a longer period.
Fort Worth, TexasAges 18 years+ - NCT07655570RecruitingPhase 2
Ivonescimab for advanced skin angiosarcoma
This trial tests a new drug called ivonescimab for people with advanced skin angiosarcoma that has spread or cannot be removed by surgery. You must have already tried a chemotherapy drug like paclitaxel or docetaxel. The goal is to see if ivonescimab can help shrink or slow the cancer.
Houston, TexasAges 18 years+ - NCT07661771RecruitingPhase 3
Personalized radiation therapy for nasopharyngeal cancer
This trial tests a new way to plan radiation treatment for nasopharyngeal cancer, where the target area is tailored to each patient's tumor spread. It aims to improve effectiveness while reducing side effects.
Dongguan, GuangdongAges 18–65 - NCT07647744RecruitingPhase 1
CD70-Targeted Cell Therapy for Advanced Kidney Cancer
This study tests a new cell-based treatment designed to target kidney cancer cells that have a protein called CD70. The treatment involves collecting your immune cells, modifying them in the lab, and infusing them back to fight the cancer. It's for patients with advanced kidney cancer who have already tried at least one standard immunotherapy.
ShanghaiAges 18–70 - NCT07646639RecruitingPhase 2
Radiation, chemotherapy, and immunotherapy for advanced rectal cancer
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Nanjing, JiangsuAges 18–70 - NCT07649070RecruitingPhase 2
Virus therapy and low-dose radiation for children with aggressive brain cancer
This trial tests whether a special herpes virus (G207) combined with low-dose radiation can help children with high-grade brain tumors (gliomas). The virus is injected into the tumor to attack the cancer cells while radiation helps boost the effect.
Houston, TexasAges 3–21 - NCT05919030RecruitingPhase 3
Tislelizumab with chemoradiation for advanced esophagus cancer
This trial tests whether adding tislelizumab to chemoradiation as the first treatment helps people with advanced esophageal squamous cell cancer. It aims to improve how well the cancer responds when it cannot be cured with surgery or full-dose curative treatment.
Wuhan, HubeiAges 18 years+ - NCT06601335RecruitingPhase 3
New immunotherapy combo for head and neck cancer
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
Wuhan, HubeiAges 18–75 - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+ - NCT07644559RecruitingPhase 2
Study of VS-7375 with cetuximab for advanced pancreatic cancer
This trial tests a new drug combination for people with a specific KRAS mutation in pancreatic cancer. It aims to see if the treatment can shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT07644585Recruiting
Ultra-High Dose Rate Radiation for Recurrent Head and Neck Cancer
This trial tests a new type of radiation therapy called ConformalFLASH that delivers radiation extremely quickly to treat head and neck cancer that has come back after previous radiation. It may help patients who cannot have surgery or have declined it.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07644650RecruitingPhase 1
Study of MST-168 for advanced solid tumors
This study tests a new drug called MST-168 for people with advanced solid tumors (cancers that have spread or can't be removed). It aims to find out if the drug is safe and effective, and how the body handles it, which could lead to a new treatment option for those who have run out of standard options.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Colorectal Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,511 recruiting colorectal cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced Colorectal Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- Metastatic Colorectal Cancer
- Locally Advanced Rectal Cancer
- Metastatic Colorectal Cancer (CRC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.